Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 19;272(9):583.
doi: 10.1007/s00415-025-13273-z.

Stratify and ImmunoWELL JCV tests performances in a real-world multiple sclerosis cohort: possible clinical implications of biosimilar Natalizumab use

Simone Guerrieri  1 , Irene Gattuso  1 , Angela Genchi  1 , Agostino Nozzolillo  1   2 , Vittorio Viti  1   3 , Chiara Zanetta  1 , Giulia D'Amore  1   3 , Maria A Rocca  1   3   4 , Lucia Moiola #  1 , Massimo Filippi #  5   6   7   8   9
Affiliations

Stratify and ImmunoWELL JCV tests performances in a real-world multiple sclerosis cohort: possible clinical implications of biosimilar Natalizumab use

Simone Guerrieri et al. J Neurol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: S Guerrieri received compensation for speaking activities from Bristol Squibb Meyer, Novartis, Merck. I Gattuso has nothing to disclose. A Genchi has nothing to disclose. A Nozzolillo has nothing to disclose. V Viti has nothing to disclose. C Zanetta received compensation for speaking activities, and/or consulting services, from Alexion, Amgen, Astrazeneca, Biogen, Bristol Myers Squibb, Janssen, Merck, Novartis, Roche, Sandoz, and Sanofi. GD'Amore has nothing to disclose. M.A. Rocca received consulting fees from Biogen, Bristol Myers Squibb, and Roche and speaker honoraria from Alexion, Biogen, Bristol Myers Squibb, Celgene, Horizon Therapeutics Italy, Merck Serono SpA, Mitsubishi-Tanabe Pharma, Neuraxpharm, Novartis, Roche, Sandoz, and Sanofi. She receives research support from the MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. She is Associate Editor for Multiple Sclerosis and Related Disorders and Associate Co-Editor for Europe and Africa for Multiple Sclerosis Journal. L Moiola received compensation for speaking activities, travel grant, and participation in advisory board from Biogen, Bristol Myers Squibb, Novartis, Roche, Sanofi-Genzyme, Merck Serono, Biogen, and Alexion. M Filippi is Editor-in-Chief of the Journal of Neurology; Associate Editor of Human Brain Mapping, Neurological Sciences, and Radiology; and received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi, speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA; participation in Advisory Boards for Alexion, Biogen, Bristol Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, and Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol Myers Squibb, Lilly, Novartis, and Sanofi-Genzyme. He receives research support from Biogen Idec, Merck Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. Ethical approval: The present study was conducted in accordance to the Helsinki Declaration (Fortaleza revision, 2013) and with European and Italian regulations about privacy. Patient gave informed consent to study inclusion and to publication of the case report.

References

    1. Greenberg B, Giovannoni G (2023) A place for biosimilars in the changing multiple sclerosis treatment landscape. Mult Scler Relat Disord. 77:104841. https://doi.org/10.1016/j.msard.2023.104841 - DOI - PubMed
    1. Tysabri: EPAR - Product information. Last updated October 17, 2024. Accessed March 11, 2025 https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri
    1. Tyruko: EPAR - Public assessment report. Reference Number: EMA/359152/2023. Published September 28, 2023. Accessed March 11, 2025 https://www.ema.europa.eu/en/medicines/human/EPAR/tyruko
    1. Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I (2017) Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol 16(11):925–933. https://doi.org/10.1016/S1474-4422(17)30282-X - DOI - PubMed
    1. Lee P, Plavina T, Castro A et al (2013) A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 57(2):141–146. https://doi.org/10.1016/j.jcv.2013.02.002 - DOI - PubMed

LinkOut - more resources